Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Inclusion Criteria: * Diagnosed with RRMS according to McDonald criteria 2010 * Relapse free within 30 days before Baseline data collection * Treatment with Rebif for 6 months or more prior to informed consent * Already using RebiSmart®2.0 + MSdialog™ for patient reported outcome (PRO) assessments (at least once prior to informed consent) * Females of childbearing potential must be willing to use appropriate contraception for the duration of the study * EDSS score less than (\<) 6 * Written informed consent obtained prior to any protocol-required data collection Exclusion Criteria: * Participation in other studies within 30 days before Baseline * Female who is pregnant or breast feeding * Significant psychiatric symptoms that, in the opinion of the Investigator, would impact subject ability to comply with treatment (as per standard clinical practice) * Any contraindication for Interferon (IFN) beta-1a therapy as per Summary of Product Characteristics (SPC) * Administration of any Multiple Sclerosis (MS) therapy, other than Rebif, within 6 months prior to informed consent